Dividend compounder review

TNGX

Tango Therapeutics Inc · NASDAQ · US

Healthcare · Biotechnology

Score31.50/100
Confidence78.00/100
DecisionInsufficient Data
RatingAvoid
Scoring

Quality breakdown

Dividend Reliability 0.0 / 25 Payment history, cuts, growth, and regularity.
Dividend Sustainability 7.0 / 20 Payout, free cash flow, dividend cover, and debt.
Business Quality 11.5 / 25 Scale, cash generation, growth, margins, and returns.
Valuation Discipline 1.0 / 15 Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend 12.0 / 15 Trend line, long return history, and drawdown control.
Metrics

Dividend and business context

Dividend Years0
Dividend Yield0.00%
Payout Ratio0.0%
Dividend Cut 5YNo
Net Income$-101.6M
Free Cash Flow$-139.9M
FCF Covers DividendUnknown
Debt / Equity8.38
P/E-
Revenue Growth 5Y52.1%
Net Margin-188.2%
ROE-38.4%
Price vs Trend90.3%
3Y Return727.3%
5Y Return181.1%
CurrencyUSD
Warnings

Review flags

No usable dividend history found.
Free cash flow is negative.
Debt to equity is elevated at 8.38.
Dividend diary

Activity record

TNGX dividend review warning Warning · Warning

Debt to equity is elevated at 8.38.